Side-by-side · Research reference

KPVvsSelank

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongDraft13/39 cited

BHuman-MechanisticDraft11/40 cited

KPV

α-MSH C-terminal · Anti-inflammatory

200–500 mcgDaily doseDalle-Pang 2024

AnimalEvidence levelDalle-Pang 2024

HoursHalf-life (est)

SQ / oral / topical · Local · Daily or 2-3×/week

Selank

Anxiolytic + Cognitive · Russian Pharma

150–300 mcg/doseIntranasalZaderej 2014

HumanMechanisticZaderej 2014 Medvedev 2007

~30 minOnset

Intranasal · 2–3×/day during stress / cognitive demand

01Mechanism of Action

Parameter

KPV

Selank

Primary target

Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024

Monoamine system (serotonin / GABA modulation) + immunomodulation via tuftsin domainZaderej 2014

Pathway

NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024

Tuftsin-derived immune signaling + CNS monoamine modulation → reduced anxiety + improved mood / cognitionMedvedev 2007

Downstream effect

Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024

Anxiolytic + cognitive enhancement; immunomodulation via increased IL-6 + IFN-γMedvedev 2007 Zaderej 2014

Feedback intact?

No melanocortin receptor binding

No GABA-receptor binding; no dependence reportedMedvedev 2007

Origin

Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024

Synthetic 7-AA peptide derived from human tuftsin (immune-system tetrapeptide)Zaderej 2014

Antibody development

—

02Dosage Protocols

Parameter

KPV

Selank

Standard dose

200–500 mcg / day SQ or oralDalle-Pang 2024

150–300 mcg / dose intranasalZaderej 2014

Frequency

Daily or 2–3× per week

2–3× per day during stress

Lower / starter dose

100 mcg / day

75 mcg / dose

Evidence basis

Animal-strong + emerging clinical data in IBDDalle-Pang 2024

Human-mechanistic + Russian clinical trialsMedvedev 2007

Duration

4–8 weeks per cycle

10–14 day cycles, repeated as needed

Reconstitution

Bacteriostatic water (SQ form)

Pre-formulated nasal spray (commercial); research vial: bacteriostatic water

Timing

No specific time; often taken with / before meals (oral)

Morning + early afternoon preferred

Half-life

Hours (estimated; rapid tissue uptake)

Short (minutes plasma); CNS effect lasts ~3 hr

04Side Effects & Safety

Parameter

KPV

Selank

Injection site reaction

Mild irritation

—

GI symptoms

Rare nausea (oral form)

—

Pigmentation

None (unlike full α-MSH)Dalle-Pang 2024

—

Long-term safety

Limited human data

Limited Western RCT data

Pregnancy / OB

Avoid — insufficient data

Nasal irritation

—

Mild burning or congestion (transient)

Sedation

—

None — distinct from benzodiazepinesMedvedev 2007

Dependence / withdrawal

—

None reported in clinical useZaderej 2014

Cognitive impairment

—

None — opposite effect (enhancement)

Allergic reaction

—

Rare hypersensitivity

Absolute Contraindications

KPV

·Pregnancy / breastfeeding

Selank

·Pregnancy / breastfeeding
·Hypersensitivity to peptide

Relative Contraindications

KPV

·Active autoimmune disease (theoretical)

Selank

·Active autoimmune disease (theoretical via immunomodulation)

05Administration Protocol

Parameter

KPV

Selank

1. Reconstitution

Add 1 mL bacteriostatic water to vial per labelling.

Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.

2. Form

SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.

Intranasal — 1–3 sprays per nostril per dose. Tilt head slightly back.

3. Timing

Morning preferred; oral form taken with / before meals.

Morning + early afternoon for cognitive demand; PRN for acute anxiety.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

Refrigerate after reconstitution; ≤30 days. Light-protected.

5. Needle

29–31G insulin syringe (SQ form).

Avoid co-administration with strong sedatives or other anxiolytics initially.

06Stack Synergy

KPV

+ BPC-157

Strong

View BPC-157 →

KPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.

KPV: 200–500 mcg oral · daily
BPC-157: 250–500 mcg oral or SQ · daily
Primary benefit: Combined anti-inflammation + mucosal repair for gut conditions

Dalle-Pang 2024 Sikiric 2018

Selank

— no documented stacks